[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Acurx Pharmaceuticals Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100632407",false,"NCT07513285","ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection","A Phase 2 Interventional, Open-Label, Single-Arm Trial of Oral Ibezapolstat (ACX-362E) for Treatment and Reduction of Recurrent Clostridioides Difficile Infection in Patients With Multiple Recurrent Infections (IBZ-PATHFINDER)","Inclusion Criteria:\n\n* Confirmed diagnosis of CDI as defined by 1) the presence of diarrhea, defined as passage of ≥ 3 UBMs within 24 hours before study Day 1, AND 2) a stool test result positive for the presence of C. difficile free toxins\n* Three or more CDI episodes in the past 12 months, including the current episode, with each episode defined as ≥ 3 unformed stools in 24 hours associated with positive C. difficile toxin test.\n* At least 1 of the protocol-qualifying prior CDI episodes, not including the current episode, has been treated with oral vancomycin or with fidaxomicin\n\nExclusion Criteria:\n\n* Severe, complicated, or life-threatening fulminant CDI with evidence of hypotension (systolic blood pressure \\\u003C 90 mmHg), septic shock, peritoneal signs or ileus, or toxic megacolon\n* Received more than 24 hours of dosing with antibiotics for the current CDI episode:\n* Received a live biotherapeutic product (LBP) (Rebyota® or Vowst™) within the past 12 weeks\n* Received or current use of anti-C. difficile antibodies, eg, IV immunoglobulin \\[IVIG\\], bezlotoxumab\n* Active inflammatory bowel disease (Crohn's disease, ulcerative colitis) with chronic diarrhea within 12 weeks before Baseline, or with a history of symptoms \\> 12 weeks before Baseline without evidence of mucosal healing on colonoscopy within the past year.\n* Active irritable bowel syndrome with chronic diarrhea in the past 12 weeks.\n* Active gastroenteritis because of Salmonella, Shigella, Escherichia coli 0157H7, Yersinia or Campylobacter, other bacteria, a parasite, or a virus within the past 2 weeks\n* Major GI surgery (eg, significant bowel resection) within 3 months of enrollment (does not include appendectomy or cholecystectomy).\n* Known current history of a severely compromised immune system","ALL","18 Years","90 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Single-arm trial to evaluate the safety and efficacy of ACX-362E \\[ibezapolstat\\] in patients with recurrent C. difficile infection (CDI).",[26],"Clostridium Difficile Infection Recurrence",[28,29,30],"Clostridioides difficile","Cdiff","Recurrent Clostridioides difficile","NOT_YET_RECRUITING","2026-04-02",{"date":34,"type":35},"2026-04-07","ACTUAL",{"date":37,"type":20},"2026-08-19",{"date":39,"type":20},"2027-11-24",{"name":41,"class":42},"Acurx Pharmaceuticals Inc.","INDUSTRY",""]